AU730324B2 - Use of protein gax for treating cancer - Google Patents

Use of protein gax for treating cancer Download PDF

Info

Publication number
AU730324B2
AU730324B2 AU74982/96A AU7498296A AU730324B2 AU 730324 B2 AU730324 B2 AU 730324B2 AU 74982/96 A AU74982/96 A AU 74982/96A AU 7498296 A AU7498296 A AU 7498296A AU 730324 B2 AU730324 B2 AU 730324B2
Authority
AU
Australia
Prior art keywords
use according
gax
adenovirus
nucleic sequence
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU74982/96A
Other languages
English (en)
Other versions
AU7498296A (en
Inventor
Didier Branellec
Patrice Denefle
Aude Le Roux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharma SA
Original Assignee
Rhone Poulenc Rorer SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer SA filed Critical Rhone Poulenc Rorer SA
Publication of AU7498296A publication Critical patent/AU7498296A/en
Application granted granted Critical
Publication of AU730324B2 publication Critical patent/AU730324B2/en
Assigned to AVENTIS PHARMA S.A. reassignment AVENTIS PHARMA S.A. Request to Amend Deed and Register Assignors: RHONE-POULENC RORER S.A.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/10—Vectors comprising a non-peptidic targeting moiety
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU74982/96A 1995-10-31 1996-10-28 Use of protein gax for treating cancer Ceased AU730324B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR95/12871 1995-10-31
FR9512871A FR2740344B1 (fr) 1995-10-31 1995-10-31 Application de la proteine gax au traitement de cancers
PCT/FR1996/001690 WO1997016459A1 (fr) 1995-10-31 1996-10-28 Application de la proteine gax au traitement de cancers

Publications (2)

Publication Number Publication Date
AU7498296A AU7498296A (en) 1997-05-22
AU730324B2 true AU730324B2 (en) 2001-03-01

Family

ID=9484112

Family Applications (1)

Application Number Title Priority Date Filing Date
AU74982/96A Ceased AU730324B2 (en) 1995-10-31 1996-10-28 Use of protein gax for treating cancer

Country Status (13)

Country Link
EP (1) EP0858466A1 (fr)
JP (1) JPH11514881A (fr)
KR (1) KR19990067174A (fr)
AU (1) AU730324B2 (fr)
BR (1) BR9611206A (fr)
CA (1) CA2233250A1 (fr)
CZ (1) CZ131598A3 (fr)
FR (1) FR2740344B1 (fr)
HU (1) HUP9900011A3 (fr)
NO (1) NO981822L (fr)
SK (1) SK56198A3 (fr)
WO (1) WO1997016459A1 (fr)
ZA (1) ZA969147B (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754822B1 (fr) * 1996-10-18 1998-11-27 Rhone Poulenc Rorer Sa Polypeptides comprenant des domaines de la proteine gax, impliques dans la repression de transcription et/ou interagissant avec d'autres proteines, acides nucleiques correspondants et leurs utilisations
WO2002000241A2 (fr) * 2000-06-28 2002-01-03 Aventis Pharma S.A. Compositions et procedes pour reguler le cycle cellulaire
KR101164602B1 (ko) 2008-01-09 2012-07-10 주식회사 케이알바이오텍 배큘로바이러스?기반 백신
WO2011055888A1 (fr) 2009-11-06 2011-05-12 Chung-Ang University Industry-Academy Cooperation Foundtion Systèmes de délivrance de gènes à base de nanoparticules
KR101232123B1 (ko) 2010-10-08 2013-02-12 연세대학교 산학협력단 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
KR101429696B1 (ko) 2012-11-21 2014-08-13 국립암센터 안전성 및 항암활성이 증가된 재조합 아데노바이러스 및 이의 용도
CN108289920A (zh) 2015-10-12 2018-07-17 汉阳大学校产学协力团 用于基因转移和基因治疗的腺病毒复合物
US11850215B2 (en) 2017-12-13 2023-12-26 Genemedicine Co., Ltd. Recombinant adenoviruses and stem cells comprising same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2705361B1 (fr) * 1993-05-18 1995-08-04 Centre Nat Rech Scient Vecteurs viraux et utilisation en thérapie génique.
US5856121A (en) * 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
FR2732357B1 (fr) * 1995-03-31 1997-04-30 Rhone Poulenc Rorer Sa Vecteurs viraux et utilisation pour le traitement des desordres hyperproliferatifs, notamment de la restenose

Also Published As

Publication number Publication date
NO981822D0 (no) 1998-04-23
KR19990067174A (ko) 1999-08-16
HUP9900011A2 (hu) 1999-04-28
JPH11514881A (ja) 1999-12-21
SK56198A3 (en) 1998-11-04
BR9611206A (pt) 1999-03-30
NO981822L (no) 1998-04-23
FR2740344B1 (fr) 1997-11-21
CA2233250A1 (fr) 1997-05-09
CZ131598A3 (cs) 1998-08-12
HUP9900011A3 (en) 1999-11-29
AU7498296A (en) 1997-05-22
ZA969147B (en) 1997-05-27
WO1997016459A1 (fr) 1997-05-09
FR2740344A1 (fr) 1997-04-30
EP0858466A1 (fr) 1998-08-19

Similar Documents

Publication Publication Date Title
US20080311608A1 (en) Antagonist of the oncogenic activity of the protein MDM2, and use thereof in the treatment of cancers
AU701345B2 (en) Viral vectors and their use for treating hyperproliferative disorders, in particular restenosis
ES2310924T3 (es) Vectores adenovirales defectivos y utilizacion en terapia genica.
JP5807236B2 (ja) 組み換えられた遺伝子発現調節配列を有する腫瘍特異的発現の改善された遺伝子伝達システム
KR20130015270A (ko) 종양 특이적 프로모터 및 이를 포함하는 종양살상 바이러스 벡터
AU730324B2 (en) Use of protein gax for treating cancer
EP1071805B1 (fr) Vecteurs adenoviraux destines au traitement de maladies
WO1995027494A1 (fr) VECTEURS DE VIRUS HERPES DEFECTIFS ET DE VIRUS ADENO-ASSOCIES DEFECTIFS COMPORTANT p53 ET DESTINES AU TRAITEMENT DU CANCER
WO2001002540A2 (fr) Vecteurs adenoviraux de traitement de maladies
AU718889B2 (en) deltaP62, its variants, nucleic acid sequences and their uses
MXPA98002924A (en) Application of the gax protein for the treatment of the cance
WO1996036365A1 (fr) Therapie genique de carcinomes hepatocellulaires par expression de genes specifiques du cancer
Gupta Current status of viral gene therapy for brain tumours
AU766153B2 (en) Use of negative regulation elements for nerve-specific expression of transgenes
Francis et al. Gene Therapy in Cardiovascular Disease: Current Status
MXPA98001407A (en) Antagonists of the oncogenic activity of the mdm2 protein, and its use in the treatment of the cance
MXPA97008877A (en) P62, its variants, the nucleic acid sequences that code them, and its use in anti-cancer gene therapy
WO1996035455A1 (fr) Therapie genique par transduction de cellules epitheliales orales
MXPA97007549A (en) Viral vectors and their use to treat disordershiperproliferativos, in particular resteno

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)